
Tech CEO ditches Apple Watch, mutes Bryan Johnson for better sleep: ‘Caused more stress than it solved'
A California-based CEO says he has gotten rid of his health monitoring devices and muted age-obsessed founder Bryan Johnson for better sleep and less stress. Alex Finn, the CEO and founder of Creator Buddy, feels that tracking and monitoring every aspect of life has a detrimental effect on one's health. Alex Finn, CEO of Creator Buddy, is rejecting the culture of excessive tracking and optimization.
'Got rid of my Apple Watch. Got rid of my Whop. Got rid of my Oura ring. Muted Bryan Johnson,' Finn declared on social media. 'No more sleep scores. No more recovery scores.
'Optimizing every part of my life caused more stress than it solved,' he said.
According to the California-based CEO, he is sleeping better after getting rid of his Apple Watch and various other health-tracking devices and muting Bryan Johnson. Bryan's Johnson's health regime
Johnson is famous for his obsession with age-reversal, a quest that sees him spending upwards of $2 million a year on a team of doctors, devices, diet plans and supplements. He follows an intensely rigorous health and longevity regimen designed to reverse his biological age and optimize every facet of his well-being.
Johnson's day involves circadian-aligned light therapy, temperature check, more than 100 pills, red light therapy, a strict exercise regime, frequent health measurements through blood biomarkers, body scans etc. He has a team of over 30 experts and hundreds of data points spanning MRI, metabolic tests, genetic markers in his quest for longevity.
This is not the lifestyle that Alex Finn wants for himself. 'We've gone too far'
Finn believes that in the coming years, people will want to lead a good old fashioned healthy lifestyle. The culture of tracking and optimization, he says, has gone too far.
'We've gone too far and I think once people realize 90% of this bro science we are all bought into is completely made up, most people will swing back to just trying to live a good, healthy life without trying to quantify every metric of their health,' wrote the CEO of Creator Buddy.
He cited a recent study claiming that glass bottles have more microplastics than plastic bottles as an example of how even the things we think are healthier can be misleading or based on flawed assumptions.
'It's all made up,' wrote Finn, adding that his new optimization routine is basically working out once in a while and not eating too much ice cream.
'Life's a lot more fun when I don't have to hit 50 benchmarks a day to convince myself I'm healthy,' he concluded.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
3 hours ago
- Business Standard
Kashmik Formulation targets ₹100 crore revenue in FY26, eyes IPO
With a growing emphasis on affordable medicines and export-led growth, Ahmedabad-based Kashmik Formulation is targeting revenue of Rs 100 crore for FY26 — more than double its FY25 topline of Rs 40 crore. The company is planning to boost production capacity and invest in automation as it eyes new markets and future growth. Kashmik Formulation is also considering an initial public offering (IPO) within the next two to three years to scale its market presence and support future growth. While aiming to be a major player, it does not expect to become a top 20 or top 10 Indian contract manufacturer in the immediate term, considering it part of a longer-term plan. Founded in 2017, the company operates at full capacity with a daily output of 10 million tablets. Kashmik is now investing Rs 20 crore to ramp up capacity by 50 per cent to 15 million tablets per day. The company currently produces around 250 million units a month and is expanding its ground and first-floor production facilities to meet the rising demand. 'Our current clients include Cipla and Dr. Lal Pathlabs. At this point, our contract manufacturing capacity is fully utilised, but once the new capacity comes online, we will look to onboard more clients,' said Nilesh Patel, managing director. Branded generics account for nearly 70 per cent of Kashmik's revenue, with contract manufacturing contributing 20–30 per cent. The company is also stepping up its export focus, aiming to increase the share of exports from the current 20 per cent to 50 per cent over the next few years. Kashmik is in the process of registering its products in semi-regulated markets such as Africa, Myanmar, and Latin America. 'We're not targeting regulated markets yet, but we're actively working to expand in semi-regulated geographies. Registration is underway, and that will be a key driver for our export ambitions,' said Patel. To improve operational efficiency, Kashmik is also investing Rs 4–5 crore in packaging automation and AI-driven solutions. While the company is not yet investing heavily in research collaborations, it has plans to set up a new research and development centre in Jammu. A foray into injectables is also on the cards, with a new facility planned within the next 3–5 years. On the pricing front, Kashmik has launched Dapagliflozin, an anti-diabetic drug under its DAPNEC brand, which the company claims is priced approximately 400 per cent lower than competing brands. 'It's a highly competitive space, but we're targeting volume growth through affordability,' said Patel. Like many Indian pharma companies, Kashmik faces challenges in active pharmaceutical ingredient (API) sourcing, especially due to heavy dependence on China. 'Cost remains a major barrier to diversifying away from Chinese APIs. Any disruption in supply from China could hit production significantly,' Patel added. Despite headwinds, the company is optimistic about its growth trajectory.
&w=3840&q=100)

Business Standard
8 hours ago
- Business Standard
Eli Lilly's weekly insulin efsitora shows positive results in Phase 3
US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora), indicating positive safety and efficacy results for A1C reduction compared to daily basal insulin. While basal insulin is a long-acting insulin administered once or twice a day, efsitora is designed for once-weekly subcutaneous injection. The company also shared detailed results from the Phase 3 QWINT-1, QWINT-3 and QWINT-4 trials. The QWINT-1 trial evaluated adults initiating insulin therapy, while QWINT-3 assessed individuals previously using daily basal insulin. QWINT-4 included participants using both basal and mealtime insulin. 'In each study, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin,' the company stated. According to Lilly, in QWINT-1, efsitora reduced A1C by 1.31 per cent compared to 1.27 per cent for insulin glargine at week 52 for the efficacy estimand. In QWINT-3, the drug reduced A1C by 0.86 per cent compared to 0.75 per cent for insulin degludec at week 26. 'In QWINT-4, efsitora reduced A1C by 1.07 per cent, matching insulin glargine's reduction of 1.07 per cent at week 26 for the efficacy estimand,' Lilly added. The Phase 3 global clinical development programme for the diabetes drug began in 2022 and included over 3,000 participants with type 2 diabetes across four global registration studies. Commenting on the results, Jeff Emmick, senior vice president of product development at Lilly, said that the once-weekly insulin therapy may offer a significant advancement for people with type 2 diabetes who need insulin, by eliminating over 300 injections a year. The company added that the drug also has the potential to provide more stable glucose levels—reducing glucose variability—throughout the week. Eli Lilly now plans to submit the drug to global regulatory agencies for the treatment of type 2 diabetes in adults by the end of 2026.


NDTV
9 hours ago
- NDTV
Are Mounjaro Jabs Safe? Mass Rollout Of Weight Loss Drug To Start In UK
For the first time, general practitioners (GPs) across the United Kingdom will be allowed to give prescriptions for a popular weight loss injection - Mounjaro, or tirzepatide. The drug, sometimes referred to as "skinny jabs", is an anti-diabetic drug made by the US-based pharmaceutical company Eli Lilly. The company said that the drug saw a "positive" response in India. The UK's National Health Service (NHS) to monitor the mass rollout that will see around 220,000 people with the "greatest need" receive the weight loss jabs over the next three years. So far, people have been able to access the drug through a special weight loss service. Now, GPs can prescribe it to severely obese people and those who are suffering from other health problems. How does Mounjaro work? It slows down the process of food digestion and also lowers blood sugar, similar to other weight loss drugs like Ozempic, Wegovy and Rybelsus. Mounjaro is used to manage type 2 diabetes and aid in weight loss. Its active ingredient, tirzepatide, works by activating two hormone receptors in the gut: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). This dual mechanism helps regulate blood sugar levels and appetite. What are the potential side effects of Mounjaro? Nausea Vomiting Diarrhea Digestive discomfort Injection site irritation Earlier this month, the UK government said that women taking popular medicines for weight loss and diabetes are being reminded to use "effective contraception" while taking these medicines. Dr Alison Cave, MHRA Chief Safety Officer, said, "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight and have not been assessed to be safe when used in this way." "Our guidance offers patients a "one stop shop" for our up-to-date advice on how to use these powerful medicines safely," Cave added. Mounjaro's positive response in India The US-based pharmaceutical company said that the drug saw a "positive" response in India and beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India. Data from research firm PharmaTrac revealed that Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May. The drug logged a 60% rise in overall sales between April and May. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said recently.